What is the step‑by‑step treatment approach for rheumatoid arthritis?

Step-by-Step Treatment of Rheumatoid Arthritis

Start methotrexate 15-25 mg weekly with folic acid 1 mg daily immediately upon diagnosis, combined with short-term low-dose glucocorticoids (prednisone 5-10 mg daily, tapered by week 8), and reassess disease activity at 3 months to determine if treatment escalation is needed. 1, 2

Initial Treatment (Week 0)

Start with methotrexate monotherapy as first-line treatment:

• Methotrexate 15 mg weekly, escalating to 20-25 mg weekly as tolerated 1, 2
• Add folic acid 1 mg daily to reduce side effects 2
• Consider subcutaneous administration if oral absorption is inadequate 2
• Add short-term glucocorticoids: prednisone 5-10 mg daily, tapered to 5 mg daily by week 8 2
• Minimize glucocorticoid use overall but recognize their disease-modifying benefits in the first 2 years 1, 2

The 2021 ACR guidelines strongly emphasize methotrexate as the anchor drug for RA treatment 1. While some older guidelines suggested initial combination therapy, the TEAR trial demonstrated that initial methotrexate monotherapy with step-up at 6 months produces equivalent outcomes to initial combination therapy, making it the more cost-effective approach 2.

First Assessment Point (3 Months)

Measure disease activity using validated composite measures (SDAI, CDAI, or DAS28):

If High Disease Activity Persists (SDAI >26 or CDAI >22):

Add a biologic DMARD immediately - the probability of achieving remission at 1 year is low without escalation 2:

• First choice: TNF inhibitor (adalimumab, etanercept, infliximab, golimumab, certolizumab pegol) plus methotrexate 1, 2
• Alternative: Abatacept (especially if contraindications to TNF inhibitors) 2
• Continue methotrexate as combination therapy is superior to monotherapy 1

If Moderate Disease Activity (SDAI 11-26 or CDAI 10-22):

Optimize methotrexate first:

• Increase to 20-25 mg weekly or maximum tolerated dose 2
• Switch to subcutaneous administration if not already done 2
• Continue to 6-month assessment

If Low Disease Activity or Remission:

• Continue current regimen
• Taper glucocorticoids to discontinuation
• Reassess at 6 months

Second Assessment Point (6 Months)

Target: Low disease activity (SDAI ≤11 or CDAI ≤10) or remission (SDAI ≤3.3 or CDAI ≤2.8) 3

If Target NOT Achieved on Methotrexate Monotherapy:

Choose one of these escalation strategies 1, 2:

1. Add biologic DMARD (preferred for faster disease control):

   • TNF inhibitor (adalimumab, etanercept, infliximab, golimumab, certolizumab pegol)
   • Abatacept (T-cell costimulation inhibitor)
   • IL-6 receptor inhibitor (tocilizumab, sarilumab)
   • Rituximab (if prior TNF inhibitor failure or lymphoproliferative disorder) 1

2. Add conventional synthetic DMARDs (triple therapy):

   • Add sulfasalazine + hydroxychloroquine to methotrexate 2
   • This is less expensive but may be slower to achieve target

3. Add JAK inhibitor (where licensed, after careful risk assessment):

   • Consider cardiovascular risk, malignancy risk, and thromboembolic risk 4
   • Generally reserved after at least one biologic DMARD trial 1

If Target NOT Achieved on Methotrexate + Biologic:

Switch to a different biologic DMARD 1, 2:

• If first TNF inhibitor fails: try another TNF inhibitor OR switch to different mechanism (abatacept, tocilizumab, rituximab)
• Abatacept is effective after TNF inhibitor failure 2
• Allow 3-6 months to assess efficacy of new biologic before switching again 2

Ongoing Management (Beyond 1 Year)

Continue treat-to-target approach with regular monitoring 3:

If Moderate/High Disease Activity Persists:

• Optimize methotrexate to 20-25 mg weekly or maximum tolerated dose 2
• Switch to subcutaneous methotrexate if not already done
• For patients on DMARD-only therapy: Add triple therapy (sulfasalazine + hydroxychloroquine) OR add biologic DMARD 2
• For patients on biologic therapy: Switch to alternative biologic with different mechanism of action 2
• Consider intra-articular glucocorticoid injections for isolated active joints 2

If Sustained Remission (≥6 months):

Consider tapering DMARDs 1:

• Taper biologics or targeted synthetic DMARDs first (dose reduction preferred over complete discontinuation) 1
• Maintain methotrexate as it has the best long-term safety profile
• Caution: Stopping often leads to flare; close monitoring required 4
• If sustained remission ≥1 year, consider one trial of de-escalation 2

Monitoring Schedule

Frequency of disease activity assessment 3:

• High/moderate disease activity: Monthly until target achieved
• Low disease activity or remission: Every 3-6 months
• Adjust therapy at least every 3 months if target not reached 3

Treatment Goals

Primary target: Clinical remission (absence of signs and symptoms of significant inflammatory disease activity) 3

Acceptable alternative: Low disease activity (particularly in established long-standing disease) 3

The overarching principle is that treatment strategy and tight control matter more than specific drug choice 5. The treat-to-target approach with frequent monitoring and rapid treatment adjustment is what drives successful outcomes, preventing joint damage and maintaining quality of life 3, 6.

Critical Pitfalls to Avoid

• Don't delay treatment: Early aggressive therapy prevents irreversible joint damage 1, 7
• Don't underdose methotrexate: Many patients need 20-25 mg weekly; consider subcutaneous route 2
• Don't wait too long to escalate: If no improvement at 3 months or target not met at 6 months, escalate immediately 3
• Don't use glucocorticoids long-term: Taper and discontinue as soon as disease control achieved 1
• Don't stop monitoring: Even in remission, assess every 3-6 months as flares can occur 3
• Don't use JAK inhibitors first-line: Reserve for after biologic failure due to cardiovascular and malignancy risks 1, 4